Irreversible electroporation for the ablation of liver tumors: Are we there yet?

Archives of Surgery

Volumn 147, Issue 11, 2012, Pages 1053-1061

  Charpentier, Kevin P ^a  

^a University Surgical Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; TRIPHENYLTETRAZOLIUM;

CANCER CELL; CELL DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISORDERS OF ACID BASE BALANCE; ECHOGRAPHY; ELECTRIC CURRENT; ELECTRIC FIELD; ELECTROCARDIOGRAM; ELECTROCHEMOTHERAPY; ELECTRON MICROSCOPY; ELECTROPORATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOTHORAX; HUMAN; IRREVERSIBLE ELECTROPORATION; LIPID BILAYER; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PNEUMOTHORAX; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SAFETY; SPRAGUE DAWLEY RAT; SYSTOLIC HYPERTENSION; TUMOR ABLATION;

AGED; AGED, 80 AND OVER; ANIMALS; CATHETER ABLATION; COHORT STUDIES; DISEASE MODELS, ANIMAL; ELECTROPORATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SAFETY; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL RATE; SWINE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84869432628     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/2013.jamasurg.100     Document Type: Review

References (85)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45 (1):8-30.
2. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271-1280. (Pubitemid 44435793)
3. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759-766. (Pubitemid 34547293)
4. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818-825, discussion 825-827.
5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318, discussion 318-321.
6. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45(10):1748-1756.
7. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23(7):1358-1364.
8. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559-565, discussion 565-567.
9. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol. 2007;14(3):1161-1169.
10. Tanaka K, Shimada H, Nagano Y, Endo I, Sekido H, Togo S. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery. 2006;139(2):263-273. (Pubitemid 43170328)
11. Timmerman RD, Bizekis CS, Pass HI, et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 2009;59(3):145-170.
12. Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol. 2004;30(4):399-406. (Pubitemid 38528924)
13. Berber E, Ari E, Herceg N, Siperstein A. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc. 2005;19(12):1613-1617. (Pubitemid 41719530)
14. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220(1):145-149. (Pubitemid 32577975)
15. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol. 2007;189(4):883-889. (Pubitemid 47479772)
16. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg. 2006;141(6):537-543, discussion 543-544.
17. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005;11(9):1117-1126. (Pubitemid 41341763)
18. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240(5):900-909. (Pubitemid 39425785)
19. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223(2):331-337. (Pubitemid 34454307)
20. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728-736.
21. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities, part I. J Vasc Interv Radiol. 2001;12(9):1021- 1032. (Pubitemid 32844849)
22. Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol. 1998;9(1, pt 1):101-111. (Pubitemid 28049697)
23. Diehn FE, Neeman Z, Hvizda JL, Wood BJ. Remote thermometry to avoid complications in radiofrequency ablation. J Vasc Interv Radiol. 2003;14(12):1569-1576. (Pubitemid 37517635)
24. Carey RI, Leveillee RJ. First prize: direct real-time temperature monitoring for laparoscopic and CT-guided radiofrequency ablation of renal tumors between 3 and 5 cm. J Endourol. 2007;21(8):807-813. (Pubitemid 47443650)
25. Crowley JM. Electrical breakdown of bimolecular lipid membranes as an electromechanical instability. Biophys J. 1973;13(7):711-724.
26. Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol. 1972;10(3):279-290.
27. Zimmermann U, Pilwat G, Riemann F. Dielectric breakdown of cell membranes. Biophys J. 1974;14(11):881-899.
28. Sugar IP, Neumann E. Stochastic model for electric field-induced membrane pores. Electroporation. Biophys Chem. 1984;19(3):211-225.
29. Benov LC, Antonov PA, Ribarov SR. Oxidative damage of the membrane lipids after electroporation. Gen Physiol Biophys. 1994;13(2):85-97.
30. Freeman SA, Wang MA, Weaver JC. Theory of electroporation of planar bilayer membranes: predictions of the aqueous area, change in capacitance, and porepore separation. Biophys J. 1994;67(1):42-56. (Pubitemid 24197868)
31. Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv Drug Deliv Rev. 1999;35(1):107-118. (Pubitemid 29046389)
32. Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg. 1999;48(1):3-16. (Pubitemid 29150357)
33. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987;78(12):1319-1321. (Pubitemid 18038276)
34. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer. 1991;27(1):68-72.
35. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope. 2001;111(1):52-56. (Pubitemid 32061951)
36. Bloom DC, Goldfarb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol. 2005;31(9):1029-1035. (Pubitemid 41671119)
37. Lee EW, Wong D, Prikhodko SV, et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol. 2012;23(1):107-113.
38. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223-231. (Pubitemid 40496051)
39. Al-Sakere B, Bernat C, Andre F, et al. A study of the immunological response to tumor ablation with irreversible electroporation. Technol Cancer Res Treat. 2007;6(4):301-306.
40. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat. 2005;4(6):699-705. (Pubitemid 43083355)
41. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality: clinical implications. Technol Cancer Res Treat. 2007;6(1):37-48. (Pubitemid 46389347)
42. Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat. 2007;6(4):313-320. (Pubitemid 47340124)
43. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat. 2007;6(4):287-294.
44. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13(3):168-173.
45. Onik G,Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295-300. (Pubitemid 47340121)
46. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;6(4):307-312. (Pubitemid 47340123)
47. Lavee J, Onik G, Mikus P, Rubinsky B. A novel nonthermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg Forum. 2007;10(2):e162-e167.
48. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford). 2010;12(5):348-351.
49. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104(1):22-28.
50. Phillips MA, Narayan R, Padath T, Rubinsky B. Irreversible electroporation on the small intestine. Br J Cancer. 2012;106(3):490-495.
51. Wendler JJ, Pech M, Blaschke S, et al. Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by nonthermal irreversible electroporation. Cardiovasc Intervent Radiol. 2012;35(2):383-390.
52. Wendler JJ, Pech M, Porsch M, et al. Urinary tract effects after multifocal nonthermal irreversible electroporation of the kidney: acute and chronic monitoring by magnetic resonance imaging, intravenous urography and urinary cytology. Cardiovasc Intervent Radiol. 2012;35(4):921-926.
53. Deodhar A, Monette S, Single GW Jr, et al. Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model. Urology. 2011;77(3):754-760.
54. Dupuy DE, Aswad B, Ng T. Irreversible electroporation in a swine lung model. Cardiovasc Intervent Radiol. 2011;34(2):391-395.
55. Deodhar A, Monette S, Single GW Jr, et al. Percutaneous irreversible electroporation lung ablation: preliminary results in a porcine model. Cardiovasc Intervent Radiol. 2011;34(6):1278-1287.
56. Appelbaum L, Ben-David E, Sosna J, Nissenbaum Y, Goldberg SN. US findings after irreversible electroporation ablation: radiologic-pathologic correlation. Radiology. 2012;262(1):117-125.
57. Schmidt CR, Shires P, Mootoo M. Real-time ultrasound imaging of irreversible electroporation in a porcine liver model adequately characterizes the zone of cellular necrosis. HPB (Oxford). 2012;14(2):98-102.
58. Guo Y, Zhang Y, Nijm GM, et al. Irreversible electroporation in the liver: contrast-enhanced inversion-recoveryMR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones. Radiology. 2011;258(2):461-468.
59. Al-Sakere B, André F, Bernat C, et al. Tumor ablationwith irreversible electroporation. PLoS One. 2007;2(11):e1135.
60. Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 2010;70(4):1555-1563.
61. Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol. 2008;180(6):2668-2674.
62. Neal RE II, Davalos RV. The feasibility of irreversible electroporation for the treatment of breast cancer and other heterogeneous systems. Ann Biomed Eng. 2009;37(12):2615-2625.
63. Neal RE, Singh R, Hatcher HC, et al. Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode. Breast Cancer Res Treat. 2010;123(1):295-301.
64. José A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317(1):16-23.
65. Pech M, Janitzky A, Wendler JJ, et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 2011;34(1):132-138.
66. Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg. 2010;110(5):1305-1309.
67. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611-621.
68. Mali B, Jarm T, Corovic S, et al. The effect of electroporation pulses on functioning of the heart. Med Biol Eng Comput. 2008;46(8):745-757.
69. Deodhar A, Dickfeld T, Single GW, et al. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol. 2011;196(3):w330-w335.
70. Narayanan G, Arora G, Barbery KJ, et al. Downstaging locally advanced pancreatic adenocarcinoma (LAPC) with vascular encasement using percutaneous irreversible electroporation (IRE). J Vasc Interv Radiol. 2012;23(3):s6-s7. doi:10.1016/j.jvir.2011.12.041.
71. Bagla S, Papadouris D, van Breda A. Percutaneous irreversible electroporation (IRE) of surgically unresectable pancreatic carcinoma: single center safety experience. J Vasc Interv Radiol. 2012;23(3):s54. doi:10.1016/j.jvir.2011.12.170.
72. Narayanan G, Hosein P, Mohin G, et al. Percutaneous irreversible electroporation (IRE) in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) to the liver. J Vasc Interv Radiol. 2012;23(3):s54. doi:10.1016/j.jvir.2011.12.171.
73. Hays D, Robbins KV, Goodwin WJ, St Amour TE. Single center, multiuser experience and safety of 50 irreversible electroporation (IRE) ablation. J Vasc Interv Radiol. 2012;23(3):s80. doi:10.1016/j.jvir.2011.01.205.
74. Cannon RM, Hays D, Goodwin W, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. HPB. 2012;14(s1):10.
75. Narayanan G, Arora G, Quintana D, et al. Vessel patency post irreversible electroporation (IRE) ablation: a 15 month follow-up. J Vasc Interv Radiol. 2012;23(3):s53. doi:10.1016/j.jvir.2011.12.168.
76. Kasivisvanathan V, Thapar A, Oskrochi Y, Picard J, Leen EL. Irreversible electroporation for focal ablation at the porta hepatis [published online February 25, 2012]. Cardiovasc Intervent Radiol. .
77. Lencioni R, Izzo F, Crocetti L, et al. A prospective, multicenter phase II clinical trial using irreversible electroporation for the treatment of early stage HCC. J Vasc Interv Radiol. 2012;23(8):1114. doi:10.1016/j.jvir.2012.05. 018.
78. Ali NS, Cohn S, Raofi V. Single center experience with irreversible electroporation for liver and pancreas tumor ablation. HPB. 2012;14(s1):2.
79. Golberg A, Rubinsky B. Towards electroporation based treatment planning considering electric field induced muscle contractions. Technol Cancer Res Treat. 2012;11(2):189-201.
80. Au JT, Wong J, Mittra A, et al. Irreversible electroporation is a surgical ablation technique that enhances gene transfer. Surgery. 2011;150(3):474-479.
81. Belkind N, Larson AC, Omary RA. Electroporation enables controlled cisplatin release from a novel drug delivery hydrogel. J Vasc Interv Radiol. 2012;23(3):s88-s89. doi:10.1016/j.jvir.2011.12.265.
82. Strasberg SM, Ludbrook PA.Who oversees innovative practice? is there a structure that meets the monitoring needs of new techniques? J Am Coll Surg. 2003;196(6):938-948. (Pubitemid 36676557)
83. Barkun JS, Aronson JK, Feldman LS, et al Balliol Collaboration. Evaluation and stages of surgical innovations. Lancet. 2009;374(9695):1089-1096.
84. Ergina PL, Cook JA, Blazeby JM, et al Balliol Collaboration. Challenges in evaluating surgical innovation. Lancet. 2009;374(9695):1097-1104.
85. McCullough P, Altman DG, Campbell WB, et al. Surgical innovation and evaluation 3: no surgical innovation without evaluation, the IDEAL recommendations. Lancet. 2009;372:1105-1112.